Roche Invests In Halozyme Biologics Delivery Platform
This article was originally published in The Pink Sheet Daily
Executive SummaryHalozyme’s Enhanze technology could be used with virtually all biologics to improve drug delivery, the company says.
You may also be interested in...
Halozyme CEO Helen Torley spoke with Scrip about execution of the company's strategy – reworked after her arrival in 2014 – to focus on oncology drug development and partnerships using its Enhanze platform.
Despite multiple partnerships around a technology platform that can ease administration of existing drugs, Halozyme says its future prospects revolve more around a significant opportunity in insulin-pump products.